Hopscotch Primary Care Raises $53M Series D

Hopscotch Primary Care raised a $53M Series D to expand its technology-enabled primary care model across rural communities. The round was led by 8VC and Town Hall Ventures, with participation from existing and new investors.

The financing matters because Hopscotch is scaling a capital-intensive clinic model in markets where physician shortages, long travel distances, and thin operating economics have defeated easier healthcare pitches. The company is betting that technology and value-based contracts can make relationship-centered primary care work beyond its original Western North Carolina base.

What Happened

Hopscotch announced the Series D on August 18, 2026. Existing investors aMoon Fund, Citi Impact Fund, Alumni Ventures, and K2 HealthVentures joined the financing, while Autism Impact Fund, John Doerr, Dr. Richard Merkin, and Leon Levine Foundation came in as new investors.

The company said the capital will deepen access in its current region, fund entry into additional rural markets, and scale its technology-powered operations. Hopscotch did not disclose its valuation, financing terms, specific expansion markets, or a clinic-opening schedule, so the important public number is the $53M round rather than an imagined price tag.

A Clinic Model Built for Rural Primary Care

Founded in 2021 by Kristin Myers Peng, Hopscotch operates primary care clinics rather than selling a software layer to existing practices. Tim Gronniger became CEO in November 2024, and Dr. Aditi Mallick currently serves as CMO.

Hopscotch focuses on older adults covered by Medicare, Medicare Advantage, or Medicare and Medicaid. Its model combines same-day visits, around-the-clock access to a care team, proactive outreach, multidisciplinary support, and technology intended to reduce administrative work and help clinicians identify patients who need attention between appointments.

Value-based contracts change the incentive structure around that care. Instead of treating each appointment as an isolated transaction, the provider takes longer-term responsibility for access, coordination, and medical spending, which makes preventive work and follow-up economically relevant. That arrangement can reward better management, but it also exposes the operator when staffing, patient engagement, or cost control falls short.

Why the $53M Series D Matters

Rural healthcare is not a smaller version of urban healthcare with prettier scenery. Lower population density changes clinic volumes, workforce recruitment, travel distances, and the economics of keeping a full care team available, which means expansion requires local operating discipline as much as software.

Hopscotch reports more than 15,000 patients across 12 clinical locations in the Southeastern United States, centered in Western North Carolina. The company also reports an NPS of 89, retention above 90%, medical-loss-ratio improvement of more than 25 percentage points over a patient's first two years, and profitable operations in Western North Carolina. Those figures come from Hopscotch and were not accompanied by independent cohort or methodology data, but they identify the claims the Series D must reproduce in new markets.

The Investor Thesis Is About Delivery, Not Just AI

John Doerr framed AI as a tool that can help clinicians care for more patients while preserving the human relationships at the center of primary care. That distinction matters because Hopscotch is applying technology inside a care-delivery operation, where an efficiency claim eventually has to survive staffing, scheduling, clinical workflows, payer contracts, and patient trust.

The round also reflects continuity in the investor base. Hopscotch's June 2024 Series C raised $50M, so the Series C and Series D represent at least $103M in publicly announced capital since then. That is not a verified all-time funding total, but it is enough to show that investors are underwriting a multi-year build rather than a quick software rollout.

Federal Rural-Health Spending Changes the Timing

The market is moving alongside a major public investment cycle. The CMS Rural Health Transformation Program will distribute $50B through states from 2026 through 2030 for rural access, workforce, facilities, technology, and value-based-care models.

Hopscotch's Series D is private financing, not a CMS award. Still, public spending can create infrastructure, partnerships, and demand in the same regions Hopscotch wants to enter, while also financing hospitals, clinics, and technology vendors competing for rural patients and clinicians.

That competition makes the federal cycle useful context rather than a free tailwind. States can support new access points and workforce programs, but every provider will still face local licensing, recruitment, payer, and referral realities. Hopscotch's advantage, if the reported Western North Carolina results hold, is a working operating model; its risk is assuming that the same playbook travels without local adaptation.

What Hopscotch Must Prove Next

Opening clinics is only the visible part of the expansion job. Hopscotch must recruit clinicians into underserved markets, maintain access and patient relationships, manage medical spending under value-based contracts, and reproduce regional operating results without assuming every town behaves like Western North Carolina.

The company has not named its next markets or promised a specific rollout pace, which is probably healthy. The Series D gives Hopscotch more room to test whether a clinic-owned rural model can scale without sanding away the very thing it sells: primary care that knows the patient before the next problem arrives.